Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus DIMETANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus DIMETANE.
CHILDREN'S ALLEGRA HIVES vs DIMETANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Dimetane (brompheniramine) is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
1-2 tablets (4-8 mg chlorpheniramine maleate) orally every 4-6 hours, not to exceed 12 tablets (48 mg) in 24 hours.
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Terminal elimination half-life is approximately 12-15 hours in adults, necessitating twice-daily or three-times-daily dosing for continuous effect.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Primarily renal excretion of metabolites, with approximately 50% of a dose excreted in urine as unchanged drug and metabolites; biliary/fecal excretion is minor (< 10%).
Category C
Category C
Antihistamine
Antihistamine